Category: <span>mesothelioma clinical trial</span>

Category: mesothelioma clinical trial

Baylor College of Medicine, chemotherapy for mesothelioma, Dr. David Sugarbaker, mesothelioma chemotherapy drugs, mesothelioma clinical trial, Mesothelioma News, mesothelioma treatment center at baylor

Sugarbaker Touts New Clinical Study for Mesothelioma Patients

 

The Mesothelioma Treatment Center at the Baylor College of Medicine Lung Institute has opened a groundbreaking clinical trial combining cytoreductive surgery with a hyperthermic, intraoperative chemotherapy lavage. Dr. David Sugarbaker, chief of thoracic surgery at Baylor and one of the world’s foremost authorities on pleural mesothelioma, believes the study could lead to a major advancement…

The post Sugarbaker Touts New Clinical Study for Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

antitumor, extending mesothelioma survival, malaria drug, malignant pleural mesothelioma, mesothelioma clinical trial, Mesothelioma News, Mesothelioma treatment, onconase, onconase clinical trial, tongji university

Study: Onconase, Malaria Drug Extends Mesothelioma Survival

 

A new treatment combining two existing drugs — one derived from frog eggs and another given to combat malaria — may be the key to extending mesothelioma survival. Scientists at Tongji University in Shanghai, China, discovered that mixing Onconase, an enzyme present in early-stage leopard frog embryos, with antimalarial drug dihydroartemisinin (DHA) synergistically suppressed growth…

The post Study: Onconase, Malaria Drug Extends Mesothelioma Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

asbestos exposure, asbestos lung cancer, KRAS lung cancer, KRAS mutation, lung cancer study, mesothelioma clinical trial, Mesothelioma News, Mesothelioma Research, Mesothelioma treatment

New Lung Cancer Study May Improve Mesothelioma Therapy

 

New insight into the gene responsible for the most aggressive subtype of non-small cell lung cancer (NSCLC) could bring hope for mesothelioma patients. Researchers from UT Southwestern Medical Center identified a new way to target lung cancer through the Kirsten rat sarcoma viral oncogene homolog, also known as the KRAS gene. Tumors that carry a…

The post New Lung Cancer Study May Improve Mesothelioma Therapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

malignant pleural mesothelioma treatment, mesothelioma cancer, mesothelioma chemotherapy, mesothelioma clinical trial, Mesothelioma News, Mesothelioma treatment, nintedanib, Ofev, rama balaraman

Researchers Test Nintedanib in Mesothelioma Clinical Trial

 

Medical oncologist Dr. Rama Balaraman isn’t expecting any miracles from the pleural mesothelioma clinical trial involving nintedanib, the small-molecule enzyme inhibitor. She is expecting progress. Balaraman, at Florida Cancer Affiliates in Ocala, is participating in an international, multicenter trial that will expand the use of nintedanib within the U.S., giving patients another weapon in this…

The post Researchers Test Nintedanib in Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

cancer treatment, city of hope cancer center, clinical trials at memorial sloan kettering, clinical trials in california, malignant pleural mesothelioma treatment, marianna koczywas, mesothelioma clinical trial, Mesothelioma News, Tazemetostat

Mesothelioma Clinical Trial for Tazemetostat Launches in US

 

City of Hope cancer center thoracic oncologist Dr. Marianna Koczywas explains the workings of tazemetostat — the latest drug tested in a mesothelioma clinical trial — with the lock and key metaphor. “You have a specific [cancer] key, and a specific keyhole it goes through. If you can lock that keyhole, you can lock it…

The post Mesothelioma Clinical Trial for Tazemetostat Launches in US appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Aduro Biotech, CRS-207, Dr. Thierry Jahan, FDA, Immunotherapy drug, malignant pleural mesothelioma, mesothelioma, mesothelioma clinical trial, Mesothelioma News, Orphan Drug Designation, U.S. Food and Drug Administration

Promising Clinical Trial Results For A Mesothelioma Immunotherapy Drug

 

Promising results from another phase of a clinical trial for an immunotherapy drug for mesothelioma, CRS-207, have been released.